

#### **ASX** announcement

25 March 2019

#### Non-Renounceable Entitlement Offer – Appendix 3B Amendment

Eneabba Gas Limited (**Eneabba** or the **Company**) confirms that further to the Appendix 3B announcement on 22 March 2019, that the fractional entitlements to the new share issue for the Non-Renounceable Entitlement Offer, will be rounded up in accordance with the prospectus lodged with the ASX on 22 March 2019.

For further information, please contact:

Barnaby Egerton-Warburton Managing Director Eneabba Gas Limited

Phone: +61 8 9467 4220

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

### **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ 01/07/96 \ \ Origin: Appendix \ 5 \ \ Amended \ 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13$ 

Name o	of entity	
Eneal	bba Gas Limited	
ABN 69 10	07 385 884	
We (tl	he entity) give ASX the following	information.
	1 - All issues st complete the relevant sections (attach	sheets if there is not enough space).
1	*Class of *securities issued or to be issued	ORD shares
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	262,066,094
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Same as existing ORD shares

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Yes
5	Issue price or consideration	\$0.003
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Non-renounceable entitlement offer  The Company intends to apply the funds raised under the offer to due diligence on potential acquisitions and general working capital purposes.
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h	Yes
	in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	19 November 2018
6c	Number of *securities issued without security holder approval under rule 7.1	N/A
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of *securities issued under an exception in rule 7.2	262,066,094	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
		Γ	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Refer Annexure 1	
7	<sup>+</sup> Issue dates	20 April 2010	
,	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	30 April 2019	
	Cross reference: item 33 of Appendix 3B.		
		NY 1	- a1
_		Number	+Class
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	786,198,281	Fully Paid Ordinary Shares

 $<sup>\</sup>boldsymbol{+}$  See chapter 19 for defined terms.

	_		
		Number	+Class
9	Number and +class of all	42,000,000	Options
	+securities not quoted on ASX	1=,000,000	exercisable at
	(including the +securities in		\$0.013 per option
	section 2 if applicable)		on or before 18
			December 2020
			December 2020
10	Dividend policy (in the case of a		
	trust, distribution policy) on the increased capital (interests)		
	increased capital (interests)		
<b>D</b>	2 B		
Part	2 - Pro rata issue		
11	Is security holder approval	No	
	required?		
10	In the increase was a laboratory	N 11	
12	Is the issue renounceable or non-renounceable?	Non-renounceable	
	renounceable:		
13	Ratio in which the *securities will	1-for-2	
13	be offered	1-101-2	
	be offered		
14	+Class of +securities to which the	Ordinary	
	offer relates		
15	<sup>+</sup> Record date to determine	28 March 2019	
	entitlements		
16	Will holdings on different	N/A	
	registers (or subregisters) be		
	aggregated for calculating		
	entitlements?		
17	Policy for deciding entitlements in	Davidina via	
17	relation to fractions	Rounding up	
	relation to mactions		
18	Names of countries in which the	All countries other th	an Australia and New
10	entity has security holders who	Zealand	an nascrana ana new
	will not be sent new offer	Zoululla	
	documents		
	Note: Security holders must be told how their		
	entitlements are to be dealt with.		
	Cross reference: rule 7.7.		
19	Closing date for receipt of	23 April 2109	

acceptances or renunciations

Appendix 3B Page 4 04/03/2013

 $<sup>\</sup>boldsymbol{+}$  See chapter 19 for defined terms.

20	Names of any underwriters	CPS Capital Group Pty Ltd
21	Amount of any underwriting fee or commission	\$47,072
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	1 April 2019
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	22 March 2019
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A

<sup>+</sup> See chapter 19 for defined terms.

32		do security holders dispose eir entitlements (except by	N/A
		nrough a broker)?	
33	<sup>+</sup> Issue	e date	30 April 2019
		Quotation of securit	
34		of <sup>+</sup> securities	igning for quocuuton of occurrates
(a)	✓	<sup>+</sup> Securities described in Part	1
(b)		All other *securities	
		•	nd of the escrowed period, partly paid securities that become fully paid, en restriction ends, securities issued on expiry or conversion of convertible
Entit	ies tha	at have ticked box 34(a)	
Additional securities forming a new class of securities			
Tick to docum		you are providing the informat	ion or
35			securities, the names of the 20 largest holders of the he number and percentage of additional *securities
36		+securities setting out the nu 1 - 1,000 1,001 - 5,000 5,001 - 10,000	v securities, a distribution schedule of the additional mber of holders in the categories
		10,001 - 100,000 100,001 and over	
37		A copy of any trust deed for t	he additional <sup>+</sup> securities

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Entiti	es that have ticked box 34(b)		
38	Number of *securities for which *quotation is sought		
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another *security, clearly identify that other *security)		
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	Number	+Class

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the 

  †securities to be quoted under section 1019B of the Corporations Act at 
  the time that we request that the †securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Gabriel Chiappini Director 25 March 2019

== == == ==

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	524,132,187	
Add the following:		
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period under an exception in rule 7.2		
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period with shareholder approval		
Number of partly paid <sup>+</sup> ordinary securities that became fully paid in that 12 month period		
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
<b>Subtract</b> the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period	Nil	
"A"	524,132,187	

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
J.	[Note: this value cannot be changed]	
Multiply "A" by 0.15	78,619,828	
<b>Multiply</b> "A" by 0.15		
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
<b>Insert</b> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:		
• Under an exception in rule 7.2		
• Under rule 7.1A		
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	Nil	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15	78,619,828	
Note: number must be same as shown in Step 2		
Subtract "C"	Nil	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	78,619,828	
	[Note: this is the remaining placement capacity under rule 7.1]	

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	524,132,187	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	52,413,218	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	Nil	
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"E"	Nil	

 $<sup>\</sup>boldsymbol{+}$  See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	52,413,218	
Note: number must be same as shown in Step 2		
Subtract "E"	Nil	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.10] – "E"	52,413,218	
	Note: this is the remaining placement capacity under rule 7.1A	

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.